<DOC>
	<DOCNO>NCT00860496</DOCNO>
	<brief_summary>A new immunosuppressive drug , base inhibition important enzyme immune system , call JAK , develop Pfizer prevent transplant rejection . Since many treatment transplant rejection may administer together , research study analyze effect common transplant rejection therapy , Tacrolimus Cyclosporine , JAK inhibitor , CP-690,550 .</brief_summary>
	<brief_title>A Phase I Open-Label Study Effects Tacrolimus Cyclosporine CP-690,555 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male 21 55 year , inclusive . Healthy female nonchildbearing potential 21 55 year , inclusive . Total body weight great 132 pound . Evidence history clinically significant disease Females childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Immunosuppression , JAK3 inhibitor , calcineurin inhibitor , tacrolimus , cyclosporine , pharmacokinetics , safety , tolerability</keyword>
</DOC>